Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

Abstract The autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell product, lisocabtagene maraleucel (liso‐cel), is administered at equal target doses of CD8+ and CD4+ CAR+ T cells. This analysis assessed safety and efficacy of liso‐cel in Japanese patients with relapsed or refractory (R/R) ag...

Full description

Bibliographic Details
Main Authors: Shinichi Makita, Go Yamamoto, Dai Maruyama, Yuki Asano‐Mori, Daisuke Kaji, Revathi Ananthakrishnan, Ken Ogasawara, Lara Stepan, Claudia Schusterbauer, Nils Rettby, Jens Hasskarl, Koji Izutsu
Format: Article
Language:English
Published: Wiley 2022-12-01
Series:Cancer Medicine
Subjects:
Japanese patients
large B‐cell lymphoma
lisocabtagene maraleucel
non‐Hodgkin lymphoma
relapsed/refractory
Online Access:https://doi.org/10.1002/cam4.4820

Similar Items

Similar Items